Skip to main content
Erschienen in: Reactions Weekly 1/2022

01.05.2022 | Case report

Corticosteroids/methotrexate/sars-cov-2-vaccine-inactivated-sinovac-biotech/tozinameran

Bullous pemphigoid, exacerbation of bullous pemphigoid and SARS-COV-2 infection: 7 case reports

Erschienen in: Reactions Weekly | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Afacan E, et al. Can Covid-19 vaccines cause or exacerbate bullous pemphigoid? A report of seven cases from one center. International Journal of Dermatology 61: 626-627, No. 5, May 2022. Available from: URL: http://doi.org/10.1111/ijd.16086 Afacan E, et al. Can Covid-19 vaccines cause or exacerbate bullous pemphigoid? A report of seven cases from one center. International Journal of Dermatology 61: 626-627, No. 5, May 2022. Available from: URL: http://​doi.​org/​10.​1111/​ijd.​16086
Metadaten
Titel
Corticosteroids/methotrexate/sars-cov-2-vaccine-inactivated-sinovac-biotech/tozinameran
Bullous pemphigoid, exacerbation of bullous pemphigoid and SARS-COV-2 infection: 7 case reports
Publikationsdatum
01.05.2022
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2022
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-022-15043-7

Weitere Artikel der Ausgabe 1/2022

Reactions Weekly 1/2022 Zur Ausgabe

Case report

Remdesivir

Case report

Clofarabine

Case report

Pembrolizumab

Case report

Mefloquine

Case report

Nivolumab